Share

March 2022; 9 (2) ArticleOpen Access

Human Leukocyte Antigen Association Study Reveals DRB1*04:02 Effects Additional to DRB1*07:01 in Anti-LGI1 Encephalitis

Vicente Peris Sempere, Sergio Muñiz-Castrillo, Aditya Ambati, Sophie Binks, Anne-Laurie Pinto, Veronique Rogemond, Sean J. Pittock, Divyanshu Dubey, Michael D. Geschwind, Jeffrey Marc Gelfand, Sonam Dilwali, Soon-Tae Lee, Julian Knight, Katherine S. Elliott, Sarosh Irani, Jérôme Honnorat, Emmanuel Mignot
First published February 3, 2022, DOI: https://doi.org/10.1212/NXI.0000000000001140
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
806

Share

Article Information

vol. 9 no. 2 e1140
DOI: 
https://doi.org/10.1212/NXI.0000000000001140
PubMed: 
35115410
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received August 23, 2021
  • Accepted in final form December 27, 2021
  • First Published February 3, 2022.
Copyright & Usage: 
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Vicente Peris Sempere, MSc* (vsempereperis{at}gmail.com),
    2. Sergio Muñiz-Castrillo, MD, PhD* (ext-sergio.muniz{at}chu-lyon.fr),
    3. Aditya Ambati, PhD (ambati{at}stanford.edu),
    4. Sophie Binks, MD (sophie.binks{at}st-hildas.ox.ac.uk),
    5. Anne-Laurie Pinto, MSc (anne-laurie.pinto{at}chu-lyon.fr),
    6. Veronique Rogemond, PhD (veronique.rogemond{at}chu-lyon.fr),
    7. Sean J. Pittock, MD (pittock.sean{at}mayo.edu),
    8. Divyanshu Dubey, MD (dubey.divyanshu{at}mayo.edu),
    9. Michael D. Geschwind, MD, PhD (michael.geschwind{at}ucsf.edu),
    10. Jeffrey Marc Gelfand, MD (jeffrey.gelfand{at}ucsf.edu),
    11. Sonam Dilwali, MD (sonam.dilwali{at}ucsf.edu),
    12. Soon-Tae Lee, MD, PhD (slee{at}snuh.org),
    13. Julian Knight, PhD (julian{at}well.ox.ac.uk),
    14. Katherine S. Elliott, PhD (kelliott{at}well.ox.ac.uk),
    15. Sarosh Irani, MD, PhD (sarosh.irani{at}ndcn.ox.ac.uk),
    16. Jérôme Honnorat, MD, PhD† (jerome.honnorat{at}chu-lyon.fr) and
    17. Emmanuel Mignot, MD, PhD†
  1. Vicente Peris Sempere, MSc* (vsempereperis{at}gmail.com),
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Sergio Muñiz-Castrillo, MD, PhD* (ext-sergio.muniz{at}chu-lyon.fr),
  3. Aditya Ambati, PhD (ambati{at}stanford.edu),
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Sophie Binks, MD (sophie.binks{at}st-hildas.ox.ac.uk),
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. SB is a co-applicant on a patent application entitled “Diagnostic Strategy to improve specificity of CASPR2 antibody detection” (PCT/GB2019/051257).

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. SB is supported by the Wellcome Trust and has previously had salary support from the National Institute for Health Research NIHR).

    Research Support, Foundations and Societies:

    1. SB holds grants from PetSavers and PetPlan charitable trust.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Anne-Laurie Pinto, MSc (anne-laurie.pinto{at}chu-lyon.fr),
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Veronique Rogemond, PhD (veronique.rogemond{at}chu-lyon.fr),
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Sean J. Pittock, MD (pittock.sean{at}mayo.edu),
    8. Scientific Advisory Boards:

    1. Alexion Pharmaceutical Advisory Board - Compensation to Mayo Clinic Medimmune/Viele Bio Advisory Board - Compensation to Mayo Clinic UCB pharmaceuticals - Personal compensation Hoffman/LaRoche - Personal compensation Roche/Genentech - Personal compensation

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. Dr. Pittock has a patent Patent# 8,889,102 (Application#12-678350) - Neuromyelitis Optica Autoantibodies as a Marker for Neoplasia issued, and a patent Patent# 9,891,219B2 (Application#12-573942) - Methods for Treating Neuromyelitis Optica (NMO) by Administration of Eculizumab to an individual that is Aquaporin-4 (AQP4)-IgG Autoantibody positive issued. Dr Pittock has a patent pending for GFAP, Septin-5, Kelch11 and MAP1B autoantibodies as biomarkers of neurological autoimmunity.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Dr. Pittock has provided consultation to Alexion Pharmaceuticals and Medimmune/Viela Bio but has received no personal fees or personal compensation for these consulting activities. All compensation for consulting activities is paid directly to Mayo Clinic. Dr. Pittock provided consultation to Astellas- Compensation to Mayo and personal compensation. Dr. Pittock received personal compensation for consultation services to UCB, Genentech, Sage Therapeutics, and Prime Therapeutics.

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. No activity to report. I am a salaried employee of Mayo Clinic and salary is fixed specialty dependent and not impacted by test volume or laboratory income.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Dr Pittock has received research funding from Grifols, Medimmune/Viela Bio, Alexion and the National Institute of Health (NIH).

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Divyanshu Dubey, MD (dubey.divyanshu{at}mayo.edu),
    9. Scientific Advisory Boards:

    1. Dr. Divyanshu Dubey has attended UCB Advisory Board Meeting in Lyon, France on September 23, 2019. All compensation for consulting activities is paid directly to Mayo Clinic.

    Gifts:

    1. Dr. Dubey has consulted for UCB, Immunovant and Astellas pharmaceuticals. All compensation for consulting activities is paid directly to Mayo Clinic.

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Dr. Dubey is on the editorial board of Journal of Clinical Medicine.

    Patents:

    1. Dr. Dubey has patent pending for Klech like protein 11 and Leucine zipper 4 as a marker of neurological autoimmunity and germ cell tumors.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Dr. Dubey has received research support from Grifols pharmaceuticals.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Michael D. Geschwind, MD, PhD (michael.geschwind{at}ucsf.edu),
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speaking honorarium from American Academy of Neurology and Wolters Kluwer Health/AudioDigest.

    Editorial Boards:

    1. Editorial board,

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Serving or has served as a consultant Clarion consulting, Microvention Terumo, Bioscience Pharma Partners, LLC (BPP), Teledoc Health, Inc., First Thought Consulting, Ascel Health LLC, LifeSci Capital LLC for consulting, ClearView Healthcare Partners, Blade Therapeutics, Inc. Consulting as medical-legal expert and expert witness for MedConnect, Wallace & Millsap, LLC, and Maupin Cox Legoy LLC.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Research support from NIH/NIA R01 AG031189 PI 2013-2020, R56 AG055619-01A 2018-2019, R01AG062562 PI 2019-2024, Alliance Biosecure 2016-18.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Michael J. Homer Family Fund

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Jeffrey Marc Gelfand, MD (jeffrey.gelfand{at}ucsf.edu),
    11. Scientific Advisory Boards:

    1. DSMB for a National Institutes of Aging funded study. Service on scientific advisory boards for Genentech/Roche.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Dr. Gelfand is on the editorial advisory board of Neurology: Neuroimmunology & Neuroinflammation. Dr. Gelfand's spouse is Editor-in-Chief of Headache and previously served on the editorial team of JAMA Neurology.

    Patents:

    1. NONE

    Publishing Royalties:

    1. Dr. Gelfand's spouse has received honoraria from UpToDate.

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Consulting for Biogen. His spouse has received prior consulting fees from Biohaven, Advanced Clinical, Theranica, and Satsuma.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research support to University of California, San Francisco from Genentech/Roche and Vigil Neuroscience. His spouse has received grant support from Amgen.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. PI of an Institutional Clinician Training Award from the National MS Society.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. Dr. Gelfand has received compensation for medical-legal consulting as an expert witness.

  11. Sonam Dilwali, MD (sonam.dilwali{at}ucsf.edu),
    12. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  12. Soon-Tae Lee, MD, PhD (slee{at}snuh.org),
    13. Scientific Advisory Boards:

    1. advisory roles for Roche/Genentech, UCB, Ono Pharmaceuticals, Biofire Diagnostics, and Advanced Neural Technologies.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  13. Julian Knight, PhD (julian{at}well.ox.ac.uk),
    14. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. Human Genetic Diversity. Functional Consequences for Health and Disease. Oxford, Oxford University Press. 2009

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Janssen

    Research Support, Government Entities:

    1. Medical Research Council, MR/V002503/1, Principal Investigator, 2020-2024

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  14. Katherine S. Elliott, PhD (kelliott{at}well.ox.ac.uk),
    15. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  15. Sarosh Irani, MD, PhD (sarosh.irani{at}ndcn.ox.ac.uk),
    16. Scientific Advisory Boards:

    1. Encephalitis Society and Autoimmune Encephalitis Alliance (non-profit, charity). ADC therapeutics, Immunovant and UCB (commercial)

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. SRI has received honoraria for speaking at scientific conferences, including the Movement Disorder Society, Dublin Neuroimunology Symposium, Korean Encephalitis meeting and Bethel Epilepsy Symposium.

    Editorial Boards:

    1. NONE

    Patents:

    1. SRI receives royalties on patent application WO/2010/046716 entitled 'Neurological Autoimmune Disorders'. The patent has been licensed for the development of assays for LGI1 and other VGKC-complex antibodies.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1. Commercial. MedImmune Ltd. 2. ADCT 3. Minnetronix Neuro Inc 4. UCB Pharma 5. Medicolegal projects (various)

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Commercial: SRI has received research funding from UCB, CSL Behring and ONO pharmaceuticals

    Research Support, Government Entities:

    1. S.R.I has received a NIHR fellowship, Department of Health, UK to fund his DPhil/PhD

    Research Support, Academic Entities:

    1. SRI received funding support from a MRC Senior Clinical Fellowship, Wellcome Intermediate Clinical Fellowship, BMA Research Grants - Vera Down grant, the Fulbright UK-US commission and the MS society (2012-2013).

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. For VGKC-complex antibody patent, as described above. Royalties paid by OUI.

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  16. Jérôme Honnorat, MD, PhD† (jerome.honnorat{at}chu-lyon.fr) and
  17. Emmanuel Mignot, MD, PhD†
    18. Scientific Advisory Boards:

    1. Kleine-Levin Syndrome Foundation: Member, Medical Advisory Board Member(non for profit) Rythm/Dreem Inc., Scientific advisory board Member (for profit) Alerion Inc, Scientific Advisory board Member (for profit) Orexin/Inoxia, Scientific Advisory board Member (no for profit)

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Jazz pharmaceuticals (for profit) Rythm/dreem (for profit) Inoxia/Orexia (for profit)

    Editorial Boards:

    1. Journal Neuropsychopharmacology: Editorial Board Member, Journal Public Library of Sciences-Biology (PLoS-Biology): Editorial Board Member Journal Sleep Medicine: Editorial board member No compensation

    Patents:

    1. NONE

    Publishing Royalties:

    1. Narcolepsy and Hypersomna, informa healthcare,Volume 220,2007

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Jazz pharmaceuticals (commercial for profit) Rythm/dreem (commercial for profit) Orexin/Inoxia (commercial for profit)

    Speakers' Bureaus:

    1. Vox Media

    Other Activities:

    1. NONE

    Clinical procedures or imaging studies:

    1. I practice sleep medicine at Stanford Health care; as such I review and interpret sleep studies and MSLTs for my patients but I am not compensated by this practice directly

    Research Support, Commercial Entities:

    1. Airweave (commercial for profit) Apple (commercial for profit) Jazz Pharmaceuticals (commercial for profit) Merck (commercial for profit) Sunovion (commercial for profit) Takeda (commercial for profit)

    Research Support, Government Entities:

    1. 1) Training grant in sleep and Genetics NIH/1T32HL110952 (Pack, Mignot, Chervin, Polotsky –PI’s) 7/13/13 – 6/30/18 Univ of Pennsylvania (Training grant) 2) KIR and HLA effects in CNS paraneoplastic syndromes and related neuroimmune conditions 1U01NS120885 (Mignot PI) 6/1/2020- 5/31/2025. Stanford University 3) Proteomic and Transcriptomic Biomarkers of Circadian Timing. 1R01HL148704-01A1 (Mignot, Czeisler PIs) 09/01/2020 – 03/31/2024. Stanford University and BWH, Boston

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. Rythm/Dreem Inc., Scientific advisory board, stock ownership Alerion Inc, Scientific Advisory board, stock ownership Inoxia/Orexia, Scientific Advisory Board, stock ownership

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Stanford University Center for Sleep Sciences (V.P.S., A.A., and E.M.), Stanford University School of Medicine, Palo Alto, CA; French Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (S.M.-C., A.-L.P., V.R., and J.H.), Hospices Civils de Lyon, Hôpital Neurologique; Synatac Team (S.M.-C., A.-L.P., V.R., and J.H.), NeuroMyoGene Institute, INSERM U1217/CNRS UMR5310, Université Claude Bernard Lyon 1, Université de Lyon, France; Oxford Autoimmune Neurology Group (S.B. and S.I.), Nuffield Department of Clinical Neurosciences, University of Oxford; Department of Neurology (S.B. and S.I.), John Radcliffe Hospital, Oxford, United Kingdom; Department of Laboratory Medicine and Pathology (S.J.P. and D.D.), and Department of Neurology (S.J.P. and D.D.), Mayo Clinic, Rochester, MN; Department of Neurology (M.D.G., J.M.G., and S.D.), University of California, San Francisco; Department of Neurology (S.-T.L.), Seoul National University Hospital, South Korea; and Wellcome Centre for Human Genetics (J.K. and K.S.E.), Nuffield Department of Medicine, University of Oxford, United Kingdom.
  1. Correspondence
    Dr. Mignot mignot{at}stanford.edu

Article usage

Article usage: February 2022 to November 2023

AbstractFullPdfSource
Feb 20228714188Highwire
Mar 20226285118Highwire
Apr 2022410453Highwire
May 202248442Highwire
Jun 202238424Highwire
Jul 20221010024Highwire
Aug 20221711034Highwire
Sep 2022189323Highwire
Oct 202277229Highwire
Nov 20221512342Highwire
Dec 2022114824Highwire
Jan 2023117016Highwire
Feb 202344014Highwire
Mar 202385326Highwire
Apr 2023154524Highwire
May 202334122Highwire
Jun 202334512Highwire
Jul 202314511Highwire
Aug 202343419Highwire
Sep 202321618Highwire
Oct 202352713Highwire
Nov 202354330Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me